期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地特胰岛素:可减少内脏脂肪量的基础胰岛素 被引量：1

Insulin detemir:a basic insulin which can reduce visceral fat
下载PDF
导出
摘要 目前肥胖在全世界呈流行趋势，成为社会公众问题。肥胖既是一个独立的疾病．又是2型糖尿病、心血管病、高血压、中风和多种癌症的危险因素．被世界卫生组织列为导致疾病负担的十大危险因素之一。我国目前体重超重者已达22．4％，肥胖者为3．01％，预防和控制肥胖症已成为刻不容缓的任务[1]。
作者 沈洁
机构地区 南方医科大学第三附属医院内分泌代谢科
出处 《药品评价》 CAS 2011年第11期13-15,共3页 Drug Evaluation
关键词 糖尿病.地特胰岛素 体重增加.内脏脂肪
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献16

  • 1中华人民共和国卫生部疾病控制司.中国成人超重和肥胖症预防控制指南[M],北京:人民卫生出版社,2006,1-20.
  • 2中国肥胖问题工作组数据汇总分析协作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值:适宜体重指数和腰围切点的研究[J].中华流行病学杂志,2002,23(1):5-10. 被引量：3332
  • 3Lau DC. Diabetes and weight management[J]. Prim Care Diabetes, 2010, 4 (Suppl 1): S24-S30.
  • 4黄慧,邓宏明,沈寒蕾,刘红,李必迅,吕泽平,唐剑,胡才有,王安平,覃保玉,杨泽.人群体脂含量与分布对胰岛素抵抗的影响[J].中国临床保健杂志,2006,9(3):195-197. 被引量：7
  • 5Braverman E. Abstract #609. Presented at: American Association of Clinical Endocrinologists 19th Annual Meeting and Clinical Congress[R]. Boston, 2010 April 21-25.
  • 6Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men[J]. Diabetes Care, 1994, 17:961-969.
  • 7UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with mefformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group[J]. Lancet, 1998, 352: 854-865.
  • 8DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group[l]. Diabetes Care, 1988,11: 567-573.
  • 9Peyrot M, Rubin RR, Lanritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study[J]. Diabetes Care, 2005, 28: 2673-2679.
  • 10沈洁.地特胰岛素减少体重增加的可能机制与临床应用[J].中国糖尿病杂志,2010,18(3):238-240. 被引量：41

二级参考文献38

  • 1张红叶,杨军,周北凡,武阳丰,李莹,陶寿淇.我国十组人群脑卒中危险因素的前瞻性研究[J].中国慢性病预防与控制,1996,4(4):150-152. 被引量：91
  • 2The Diabetes Control and Complications Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care, 1995,18 : 1415-1427.
  • 3UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998,352: 837 -853.
  • 4Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1997,82 : 4037-4043.
  • 5DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care, 1988,11 : 567-573.
  • 6Lin X, Taguchi A,Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and dia betes. J Clin Invest,2004,114:908-916.
  • 7Brunner GA, Sendhofer G, Wutte A, et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes, 2000,108 : 100-105.
  • 8Havelund S, Ribel U, Plum A, et al. The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes, 2004,53 : P462.
  • 9Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insu lins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 2004,47 : 622-629.
  • 10Raslovd K, Bogoev M, Raz I,et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract, 2004,66:193-201.

共引文献3620

同被引文献7

引证文献1

药品评价
2011年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部